Revive Therapeutic (RVV.C) announced they have entered into an agreement with the University of Health Sciences Antigua (UHSA) to collaborate with Revive on their novel psychedelic-assisted therapies and pioneering…
RVV
Revive Therapeutics (RVV.C) signed a research agreement with the University of California, San Francisco (UCSF) to explore Bucillamine as a potential treatment for severe cases of COVID-19 today, according…
“Psilocybin offers a potential solution to manage moderate to severe cases of TBI,” stated RVV, “Psilocybin has the potential with its neuroreparative effect to improve loss of cognitive function…
Pfizer & Moderna – two very different companies President Biden’s goal to vaccinate between 70% and 85% of the U.S. population, which is roughly 230 million – 280 million…
+135k shares in a downturn, my man The psychedelics sector is down bad this week. Just look at the psychedelics ETF PSYK.NE. It’s not an alarm or…
Revive Therapeutics (RVV.C) provided an update on their Phase 3 clinical trial for bucillamine for COVID-19 today. Primarily, the update’s about funding and more specifically their recent $23 million…
Revive Therapeutics (RVV.C) advanced the December 21 deal with Newscope Capital (PHRM.C) past a binding LOI and into a purchase agreement to acquire psilocybin intellectual property from Newscope’s subsidiary,…
Revive Therapeutics (RVV.C) and 17 other companies in the United States and Canada joined the first psychedelic exchange-traded fund, managed by Horizons ETF management today, according to a press…
Revive Therapeutics (RVV.C) entered into a sponsored research agreement and license agreement with North Carolina State University (NC State), developing a biosynthetic version of psilocybin today, according to a…
On December 20, 2020, Revive Therapeutics (RVV.C) inked a non-binding letter of intent for the full rights to PharmaTher’s psilocybin intellectual property, according to a press release. PharmaTher is…